Frequency of VTE risk factors and bleeding risks
| Study period | November 2009 (1) | January 2010 (2) | April 2010 (3) | April 2011 (4) | Totals |
|---|---|---|---|---|---|
| Total admitted | 265 | 255 | 239 | 256 | 1015 |
| Case notes available | 232/265 (87.5%) | 216/255 (84.7%) | 204/239 (85.4%) | 224/256 (87.5%) | 876/1015 (86.3%) |
| At least 1 VTE risk factor* | 192/232 (82.8%) | 172/216 (79.6%) | 161/204 (78.9%) | 195/224(87.1%) | 719/876 (82.1%) |
| 95% CI | (77.3% to 87.4%) | (73.6% to 84.8%) | (72.7% to 82.3%) | (82.9% to 91.1%) | (79.4 to 84.6%) |
| At least one bleeding risk factor* | 44/232 (19.0%) | 62/216 (28.7%) | 53/204 (26.0%) | 63/224 (28.1%) | 222/876 (25.3%) |
| 95% CI | (14.1% to 24.6%) | (22.8% to 35.2%) | (20.1% to 32.6%) | (22.3% to 34.5%) | (22.5% to 28.4%) |
| Risk factors for both VTE and bleeding* | 34/232 (14.7%) | 44/216 (20.4%) | 43/204 (21.1%) | 50/224 (22.3%) | 171/876 (19.5%) |
| 95% CI | (10.4% to 19.9%) | (15.2% to 26.4%) | (15.7% to 27.3%) | (17.0% to 28.3%) | (16.9% to 22.3%) |
| VTE risk and no bleeding risk* (LMWH indicated) | 158/232 (68.1%) | 128/216 (59.3%) | 118/204 (57.8%) | 145/224 (64.7%) | 549/876 (62.7%) |
| 95% CI | (61.7% to 74.1%) | (52.4% to 65.9%) | (50.7% to 64.7%) | (58.1% to 71.0%) | (59.4% to 65.9%) |
*No significant difference between study periods.
LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.